NCT02146703View on ClinicalTrials.gov

Gemcitabine and S-1 for Advanced Biliary Tract Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

November 30, 2010

Study Completion Date

December 31, 2013

Conditions
Biliary Tract Neoplasm
Interventions
DRUG

Gemcitabine, and S-1

"Treatment will be delivered as a 3-week cycle.~1. Gemcitabine 1000 mg/m2 iv on day 1, 8~2. S-1 60 mg/day po on day 1-14"

Trial Locations (1)

Unknown

Hallym University Medical Center, Anyang

Sponsors
All Listed Sponsors
collaborator

Jeil Pharmaceutical Co., Ltd.

INDUSTRY

lead

Hallym University Medical Center

OTHER

NCT02146703 - Gemcitabine and S-1 for Advanced Biliary Tract Cancer | Biotech Hunter | Biotech Hunter